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Abstract
Background: Carvedilol has been shown to be superior to metoprolol tartrate to improve clinical outcomes in
patients with heart failure (HF), yet the mechanisms responsible for these differences remain unclear. We examined
if there were differences in endothelial function, insulin stimulated endothelial function, 24 hour ambulatory blood
pressure and heart rate during treatment with carvedilol, metoprolol tartrate and metoprolol succinate in patients
with HF.
Methods: Twenty-seven patients with mild HF, all initially treated with carvedilol, were randomized to a two-
month treatment with carvedilol, metoprolol tartrate or metoprolol succinate. Venous occlusion plethysmography,
24-hour blood pressure and heart rate measurements were done before and after a two-month treatment period.
Results: Endothelium-dependent vasodilatation was not affected by changing from carvedilol to either metoprolol
tartrate or metoprolol succinate. The relative forearm blood flow at the highest dose of serotonin was 2.42 ± 0.33
in the carvedilol group at baseline and 2.14 ± 0.24 after two months continuation of carvedilol (P = 0.34); 2.57 ±
0.33 before metoprolol tartrate treatment and 2.42 ± 0.55 after treatment (p = 0.74) and in the metoprolol
succinate group 1.82 ± 0.29 and 2.10 ± 0.37 before and after treatment, respectively (p = 0.27). Diurnal blood
pressures as well as heart rate were also unchanged by changing from carvedilol to metoprolol tartrate or
metoprolol succinate.
Conclusion: Endothelial function remained unchanged when switching the beta blocker treatment from carvedilol
to either metoprolol tartrate or metoprolol succinate in this study, where blood pressure and heart rate also
remained unchanged in patients with mild HF.
Trial registration: Current Controlled Trials NCT00497003
Keywords: Heart failure, Endothelial function, Beta blocker
Introduction
Beta blocker treatment is a well-established therapy for
heart failure (HF), but the drugs tested have different
profiles of possible clinical consequence. In the Carvedi-
lol Or Metoprolol European Trial (COMET) treatment
with carvedilol was found superior in patients with
chronic heart failure when compared to metoprolol tar-
trate [1].
Patients with heart failure are characterized by having
an impaired endothelial function regardless of the etiol-
ogy of heart failure [2]. An impaired endothelial func-
tion in patients with heart failure is associated with a
poor prognosis [3,4] and the severity of endothelial
function in HF is proportional to the New York Heart
Association heart failure classification (NYHA) in HF
[3]. We therefore designed this study to investigate
whether metoprolol tartrate, metoprolol succinate and
carvedilol respectively affect vascular endothelial func-
tion and vascular insulin resistance differently in
patients with chronic heart failure.
* Correspondence: bk@heart.dk
1Department of Cardiology, Gentofte Hospital, Hellerup, Denmark
Full list of author information is available at the end of the article
Falskov et al. Cardiovascular Diabetology 2011, 10:91
http://www.cardiab.com/content/10/1/91
CARDIO
VASCULAR 
DIABETOLOGY
© 2011 Falskov et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Patients with HF are at increased risk of developing
diabetes and frequently demonstrate insulin resistance
[5,6]. In the Carvedilol Or Metoprolol European Trial
(Comet) study it was observed that metoprolol deterio-
rates metabolic glucose control whereas carvedilol does
not [7] and, accordingly, there was a larger number of
new-onset diabetes in patients treated with metoprolol
[8]. We have observed that vascular insulin sensitivity
was deteriorated after treatment with metoprolol in
patients with type 2 diabetes, whereas no change was
found after treatment with carvedilol [9]. We hypothe-
sized that changes in endothelial insulin sensitivity might
be involved in the processes by which survival is different
during treatment with carvedilol and metoprolol.
The beta-1 adrenergic receptor blocking effect of
metoprolol tartrate has been doubted to be as effective
as the beta-1 adrenergic blocking effect of both carvedi-
lol and metoprolol succinate [10]. We therefore per-
formed a 24-hour ambulatory blood pressure
measurement as well as heart rate measurements in
patients receiving either carvedilol, metoprolol tartrate
or metoprolol succinate to evaluate potential differences
in the adrenergic effects among three treatment groups.
We aimed to find potential differences among beta
blockers, when used in recommended doses, to obtain
what is thought to be equivalent treatment doses.
Method and materials
Population
Thirty patients with mild heart failure (HF) were
included in the study. Inclusion criteria were heart fail-
ure with a Left Ventricular Ejection Fraction (LVEF) of
35% or below, documented by echocardiography at the
time of entering the study and stable NYHA class I-II.
Decompensated heart failure, beta blocker intolerance,
uncontrolled hypertension, hypotension and bradycardia
were all exclusion criteria for entering the study.
Patients were secondarily excluded from the study if
they became clinically unstable or had to change medi-
cal treatment during the study period. Ten volunteers
with no documented cardiovascular disease, no diabetes
and no medication use were enrolled as control group
for comparison on baseline measurements.
Patient recruitment was done by advertisement in
newspapers and from an out-patients clinic. Informed
consent was given before entering the study. The study
was approved by the ethics committee of the city of
Copenhagen (ref KF 02-071/03), as well as the Danish
Medicines Agency (ref 2612-2423) and registered at
clinical trials.gov (ref NCT00497003).
Design
Before randomization all patients were treated with car-
vedilol for at period of at least two months to ensure
equal use of beta blockers at baseline. Patients receiving
beta blocker treatment at the time they were included in
the study, had their beta blocker treatment changed to
carvedilol. If the patients were beta blocker naïve at the
time of inclusion, they started treatment with carvedilol
and titrated to the highest tolerable dose. The patients
were then randomized to receive treatment with carve-
dilol, metoprolol tartrate or metoprolol succinate for a
period of two months. The group of patients who con-
tinued on carvedilol treatment served as time-control.
Patients were otherwise kept on their usual medication
throughout the whole study period.
Ten patients were randomized to receive carvedilol
with a target dose of 50 mg a day; ten patients were ran-
domized to receive metoprolol succinate with a target
dose of 200 mg a day and ten patients were randomized
to receive metoprolol tartrate with a target dose of 200
mg a day.
The study was designed as an open parallel group
study. Before and after the two months randomization
period an examination of endothelial function as well as
insulin stimulated endothelial function was performed
by venous occlusion plethysmography as described in
the following section. Forearm glucose uptake was mea-
sured during intra-arterial insulin infusion both before
and after the treatment period. 24 hour blood pressure
and heart rate measurements were also done before and
after the two months randomization period.
Venous occlusion plethysmography
Endothelial function was measured by using the method
venous occlusion plethysmography as described before
[11]. Venous occlusion plethysmography is an invasive
technique in which vasoactive agents are infused directly
into the artery. The technique allows us to test a vasoac-
tive response to different agents without systemic
changes. Additionally we tested the vasoactive properties
of insulin as well as direct insulin stimulated glucose-
uptake in the forearm. Venous occlusion plethysmogra-
phy has been found to be a valid method of measuring
endothelial function [12].
Examinations were done after an overnight fast, in a
q u i e tr o o mw i t ht h et e m p e r a t u r ek e p tc o n s t a n td u r i n g
t h ed a y .T h ep a t i e n t sw e r ea l la b s t i n e n tf r o ms m o k i n g
for at least 8 hours and did not take their usual medica-
tion in the morning before examination. Examinations
were done with the patients lying supine with the fore-
arm at a horizontal level with the right atrium.
Endothelium-dependent vasodilatation was assessed
stepwise after an intra-arterial infusion of increasing
doses of serotonin (7, 21, 70 ng/min) [Serotonin (Clin-
alfa, Läufelfingen, Switzerland)] for 4 minutes at each
dose level to achieve a dose-response profile. Serotonin
is an agonist of endothelial nitric oxide (NO)
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was assessed by infusion of increasing doses of nitro-
prusside [Nitropress (Abbott Laboratories, North Chi-
cago, IL)] (0.5, 1 and 1.5 μg/min). Nitroprusside is an
external NO donor in vascular smooth muscle cells and
provide vascular smooth muscle relaxation and dilata-
tion. To assess insulin-stimulated endothelial vasodilata-
tion, insulin [Actrapid (Novo Nordisk Scandinavia,
Malmö Sweden) in a 1% human albumin solution (vehi-
cle)] was co-infused with serotonin. Insulin was infused
intra-arterially for 60 minutes prior to the vaso-reactivity
studies with serotonin, at a rate of 0.05 mU/kg body
weight/min. Studies with co-infusions of N
G-mono-
methyl-L-arginine [L-NMMA (Clinalfa, Läufelfingen,
Switzerland)], serotonin and insulin were done to deter-
mine the NO-dependent fraction of the insulin-stimu-
lated endothelium-dependent vasodilatation. L-NMMA
is a non-specific NO synthase inhibitor. Flow measure-
ments are presented as the relative blood flow, given as
a proportion between the actual blood flow (ml/min) in
the infused arm and the actual blood flow in the non-
infused arm. All evaluation of blood flow was performed
blinded to treatment allocation.
Forearm Glucose uptake
Blood samples were drawn simultaneously from a cathe-
ter placed intravenously in the infused arm, a catheter
placed in the brachial artery of the infused arm, and a
catheter placed intravenously in the non-infused arm.
The latter served as a control for systemic changes in
concentrations of insulin and glucose during intra-arter-
ial infusion of insulin. Forearm glucose uptake was cal-
culated as the arterio-venous difference in glucose
concentration in relation to forearm blood flow in sam-
ples from the artery and vein of the infused arm, respec-
tively, and done on both examination days-before and
after the two-month treatment period with either of the
three beta blockers. Plasma glucose concentrations were
determined by the glucose oxidase method [Vitros
Chemistry; Johnson & Johnson, Rochester New York]
and serum insulin concentrations by a chemilumines-
cent immunometric assay [Immulite 2500; DPC, USA].
Measurements of systemic metabolic changes of insulin
resistance were calculated with the use of a computerized
Homeostatic model assessment calculator [(HOMA2) Dia-
betes Trial Units, The Oxford Centre for Diabetes, Endo-
crinology and Metabolism]. The used formula for the
calculations: HOMA Insulin Resistance = (Fasting Plasma
Insulin (mU/L) × Fasting Plasma Glucose (mmol/L))/22.5.
24 hour ambulatory blood pressure and measurements of
heart rate
Changes in blood pressure and heart rate were exam-
ined in a sub-group of patients in all three treatment
groups. Patients had a 24-hour ambulatory blood pres-
sure and heart rate examination done on a separate day
before and after the randomized treatment period. An
ambulatory blood pressure monitor was used [Model
TM-2430; A&D Instruments ltd., Oxford, UK] and com-
puter software was used for retrieving data [EZ Doctor
Software for TM-2430; Kivex A/S, Hørsholm, Denmark].
Statistics
Results are expressed as means ± standard error of
mean (SEM), unless otherwise specified.
Comparisons of baseline differences between the
groups were performed using unpaired Students t-test.
Paired comparisons after the treatment or observation
period were analyzed with students paired t-test. Differ-
ences between groups for single parameters after the
treatment with either of the t h r e eb e t ab l o c k e r sw e r e
compared with 2-way analysis of variance (ANOVA).
Changes in forearm blood flow as well as changes in
forearm glucose uptake were subject to analysis of var-
iance for repeated measurements using the proc mixed
procedure in the Statistical Analyses Software, version
8.0 (SAS Institute, Cary, NC, USA). Forearm glucose
uptake measurements were logt r a n s f o r m e dt os a t i s f y
assumptions of normal distribution and homogeneity of
variance of residuals. Subjects entered the model as ran-
dom effect. The dose of vasodilator and the interaction
between insulin and serotonin entered the model as
fixed values.
Multivariable association between flow, treatment and
other cofactors was examined in mixed variance covar-
iance models using proc mixed from SAS. Individual
and interaction between study and individual were ran-
dom variables whereas cofactors and interaction
between study day and treatment were entered as fixed
variables.
From previous studies in our group [11] it was found
that a sample size of 10 patients in each group, a differ-
ence of 20% in forearm blood flow and forearm glucose
uptake can be found with a statistical significance of 5%.
Results
B o t hm e na n dw o m e nw e r ei n c l u d e di nt h es t u d ya n d
they were at the age 46 to 80 years old at the time the
study took place. Three patients were excluded from the
study after randomization, one in each treatment group.
Two patients were excluded due to difficulties in cannu-
lation at the second examination day and one patient
was excluded because of an episode of unstable angina
during the treatment period. Therefore nine patients in
each treatment group completed the study.
The carvedilol doses achieved at baseline were similar
in the three groups: 37.2 ± 5.3 mg a day in the group
that was randomized to continue on carvedilol, 36.8 ±
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prolol succinate treatment and 34.0 ± 6.5 mg a day in
the group that was switched to metoprolol tartrate.
After randomization and through the two-month treat-
ment period, the doses of the respective treatments
were as follows: 37.2 ± 5.3 mg a day of carvedilol, 147.2
± 22.2 mg of metoprolol succinate and 130.6 ± 24.9 mg
a day of metoprolol tartrate.
Baseline data and changes after the two-month treat-
ment period are shown in table 1 for all three treatment
groups as well as baseline data for the healthy control
group. Nine, seven and four patients in the carvedilol,
metoprolol succinate and metoprolol tartrate group
respectively, received either an angiotensin-converting
enzyme (ACE) inhibitor or an angiotensin II receptor
antagonist (AT II antagonist). The use of statins as well
as aspirin was equal in all three treatment groups. After
initial screening, patients who were using other beta
blockers than carvedilol were changed to carvedilol and
those who where not using any, were initiated to treat-
ment with carvedilol and titrated to the highest tolerable
dose.
Before randomization, patients in the metoprolol tar-
trate group had a lower fasting glucose and HgbA1c
than the other treatment groups (p < 0.05) (table 1).
This could be explained by the fact that there were
three patients with type 2 diabetes included in the car-
vedilol as well as the metoprolol succinate group and
none in the metoprolol tartrate group. In the carvedilol
group glycosylated hemoglobin (HgbA1c) was also lower
after the two months treatment period (p < 0.01).
Patients in the metoprolol succinate as well as the
time control group-the group kept on carvedilol treat-
ment-tended to have a lower high-density lipoprotein
(HDL) level after the two months treatment. In the car-
vedilol group the HDL level was 1.47 ± 0.20 mmol/l
before randomization and 1.24 ± 0.20 mmol/l two
months after randomisation (p < 0.05). In the
Table 1 Baseline characteristics of the patients randomized to carvedilol, metoprolol succinate and metoprolol tartrate
before and after the treatment period, and baseline characteristics of the healthy control group
Carvedilol
(N = 9)
Metoprolol Succinate
(N = 9)
Metoprolol Tartrate
(N = 9)
Healthy
controls
(N = 10)
Before
treatment
After
treatment
Before
treatment
After
trreatment
Before
treatment
After
treatment
Age 67.1 ± 3.31 63.6 ± 2.02 60.3 ± 3.26 47.6 ± 1.89
Sex (Female/Male) 2/7 2/7 1/8 5/5
Smokers (Y/N) 4/5 1/8 2/7 0
Diabetes (Y/N) 3/6 3/6 0/9 0
NYHA I (N°) 545 0
NYHA II (N°) 454 0
ACE I/ATII ant (Y/N) 9/0 7/2 5/4 0
Aspirin (Y/N) 6/3 6/3 7/2 0
Statins (Y/N) 7/2 8/1 7/2 0
CRP < 10 < 10 < 10 < 10 < 10 < 10 < 10
Hgb (mmol/l) 8.1 ± 0.30 7.97 ± 0.34 8.48 ± 0.23 8.37 ± 0.33 8.54 ± 0.19 8.47 ± 0.16 8.00 ± 0.21
Total Cholesterol
(mmol/l)
3.88 ± 0.23 3.89 ± 0.30 4.21 ± 0.27 3.96 ± 0.22 3.88 ± 0.18 3.81 ± 0.19 4.5 ± 0.29
Triglyceride (mmol/l) 1.57 ± 0.40 1.35 ± 0.20 1.66 ± 0.41 1.74 ± 0.31 1.57 ± 0.38 1.57 ± 0.36 0.9 ± 0.17
HDL (mmol/l) 1.47 ± 0.20 1.24 ± 0.20
3 1.44 ± 0.16 1.15 ± 0.11
3 1.34 ± 0.12 1.27 ± 0.13 1.4 ± 0.14
LDL (mmol/l) 1.88 ± 0.17 2.03 ± 0.24 2.24 ± 0.31 2.03 ± 0.24 1.80 ± 0.24 1.88 ± 0.27 2.7 ± 0.26
Hgb A1c (%) 6.12 ± 0.20 5.91 ± 0.23
3 6.78 ± 0.49 6.73 ± 0.51 5.64 ± 0.10¹
2 5.5 ± 0.25
2 5.24 ± 0.10
Plasma-Glucose 6.30 ± 0.29 6.24 ± 0.69 5.73 ± 0.42 5.82 ± 0.49 5.19 ± 0.26¹ 5.14 ± 0.31
Serum-Insulin 24.80 ± 11.72 27.50 ± 12.96 9.72 ± 2.52 17.67 ± 4.71 8.52 ± 2.93 8.32 ± 3.48
HOMA-IR 1.86 ± 0.67 1.77 ± 0.37 1.33 ± 0.34 1.87 ± 0.62 1.11 ± 0.40 1.33 ± 0.56
Body weight (kg) 77.58 ± 6.60 77.47 ± 6.74 90.21 ± 6.17 90.19 ± 6.40 86.82 ± 3.53 87.59 ± 3.99 75.62 ± 4.24
BMI (kg/m
2) 26.37 ± 1.23 26.32 ± 1.27 29.41 ± 1.63 29.38 ± 1.65 28.1 ± 0.84 28.31 ± 0.98 24.4 ± 0.93
¹p < 0.05 for comparison between metoprolol tartrate and carvedilol
2p < 0.05 for comparison between metoprolol tartrate and metoprolol succinate
3p < 0.05 change from before and after randomization treatment
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1.44 ± 0.16 mmol/l to 1.15 ± 0.11 before and after ran-
domization, respectively (p < 0.05). HDL level in the
metoprolol tartrate group was unchanged through the
study period.
Vaso-reactivity studies
The group of patients with HF had a slightly but not
significantly lower response to serotonin compared to
the group of healthy controls (Figure 1a), while insulin-
stimulated endothelial function was markedly reduced in
this group (Figure 1b).
Endothelium-dependent vasodilatation assessed with
infusion of increasing doseso fs e r o t o n i nw a se q u a li n
the three groups before randomization and did not
change after switching beta blocker treatment from
carvedilol to metoprolol succinate or metoprolol tar-
trate: In the group randomized to metoprolol succinate
the relative forearm blood flow was 1.24 ± 0.11; 1.21 ±
0.12; 1.54 ± 0.19; and 1.82 ± 0.29 at each dose level of
serotonin before randomization treatment and 1.38 ±
0.16; 1.43 ± 0.15; 1.68 ± 0.26; and 2.10 ± 0.37 after two
months treatment with metoprolol succinate (p = 0.27)
(Figure 2a). In the group randomized to metoprolol tar-
trate the relative blood flow was 1.17 ± 0.08; 1.36 ±
0.19; 1.79 ± 0.18 and 2.57 ± 0.33 before randomization
and 1.38 ± 0.23; 1.30 ± 0.21; 1.79 ± 0.34 and 2.42 ± 0.55
after the treatment period (p = 0.74) (Figure 2b). The
third group was kept on carvedilol treatment after ran-
domization and blood flow did not change during the
treatment period: The blood flow was 1.18 ± 0.10; 1.25
± 0.11; 1.87 ± 0.16 and 2.42 ± 0.33 before randomiza-
tion and 1.24 ± 0.07; 1.22 ± 0.08; 1.80 ± 0.12 and 2.14 ±
0.24 after randomization treatment period (p = 0.34)
(Figure 2c).
Switching beta blocker treatment did not affect insu-
lin-stimulated endothelial function significantly: The
percentage change in forearm blood flow in patients
randomized to stay on carvedilol treatment for each ser-
otonin dose was 33.58% ± 10.97; 24.74% ± 15.21 and
24.92% ± 21.86 before randomization and 33.56% ±
12.10; 28.72% ± 17.77 and 16.45% ± 31.46 after the
treatment period (p = 0.84) (Figure 3a). In the metopro-
lol succinate group the percentage change in flow was
28.71% ± 8.36; 10.27% ± 12.00 and 40.78% ± 20.19
before treatment with metoprolol succinate and 7.03% ±
8.69; 12.82% ± 16.13 and 17.09% ± 15.01 after two
months treatment (p = 0.29) (Figure 3b). In the meto-
prolol tartrate group the percentage change in flow was
11.19% ± 6.45; 2.08% ± 10.38 and -9.55% ± 16.51 before
randomization and 15.03% ± 9.26; 42.48% ± 9.69 and
20.22% ± 29.79 after treatment (p = 0.48) (Figure 3c).
Studies of endothelium-independent vasodilatation with
sodium nitroprusside were also not affected by the change
in beta blocker treatment (data not shown). L-NMMA co-
infusion with both insulin and serotonin abolished the sti-
mulated vasodilatation and was unchanged in the three
treatment groups (data not shown).
Other analysis
Multivariable analysis of the relation between treatment
(carvedilol, metoprolol tartrate and metoprolol succi-
nate) and serotonin induced flow also revealed no rela-
tion when diabetes, ACE inhibitor or AT antagonist
treatment, treatment with statins, smoking, NYHA class,
left ventricular ejection fraction (LVEF) and body mass
index (BMI) were also entered in the analysis (p = 0.36).
Also insulin induced flow changes were not changed by
treatment when tested with multivariable analysis (p =
0.32).
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Figure 1 Baseline flow. Comparison of the forearm blood flow
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infusion of Insulin between patients with heart failure and healthy
controls respectively.
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metoprolol succinate, metoprolol tartrate and carvedilol respectively.
Dose Serotonin [ng/min]
72 1 7 0
%
 
C
h
a
n
g
e
 
i
n
 
f
o
r
e
a
r
m
 
b
l
o
o
d
f
l
o
w
-40
-20
0
20
40
60
80
At baseline with Carvedilol
After randomization to Carvedilol
p=0.84
Dose Serotonin [ng/min]
72 1 7 0
%
 
c
h
a
n
g
e
 
i
n
 
f
o
r
e
a
r
m
 
b
l
o
o
d
f
l
o
w
-40
-20
0
20
40
60
80
Before Metoprolol Succinate
After Metoprolol Succinate
p=0.29
Dose Serotonin [ng/min]
72 1 7 0
%
 
C
h
a
n
g
e
 
i
n
 
f
o
r
e
a
r
m
 
b
l
o
o
d
f
l
o
w
-40
-20
0
20
40
60
80 Before Metoprolol Tartrate
After Metoprolol Tartrate
p=0.48
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The group of patients with HF had impaired forearm
g l u c o s eu p t a k ec o m p a r e dt oh e a l t h yi n d i v i d u a l s( F i g u r e
4). During insulin infusion,f o r e a r mg l u c o s eu p t a k ei n
the carvedilol group was similar throughout the study:
Glucose uptake after 30 minutes of insulin infusion,
increased from 1.12 mmol/min ± 0.19 to 1.97 mmol/
min ± 0.51 and to 2.22 mmol/min ± 0.42 after 60 min-
utes of infusion on the first examination day with a
similar increase seen on the second examination day
with an forearm glucose uptake of 1.19 mmol/min ±
0.16 to 1.86 mmol/min ± 0.52 after 30 minutes and 2.19
mmol/min ± 0.69 after 60 minutes (p = 0.94 between
the two days) (Figure 5a). Switching carvedilol to meto-
prolol succinate or to metoprolol tartrate did not affect
glucose uptake either, as it i ss h o w ni nF i g u r e s5 ba n d
5c, (p = 0.58 between treatment with carvedilol and
metoprolol succinate and p = 0.92 between treatment
with carvedilol and metoprolol tartrate).
As expected, serum-insulin concentration increased in
the infused arm during insulin infusion and this increase
did not change between treatment groups or from day 1
to day 2 (data not shown). Systemic serum-insulin con-
centrations were kept constant during the intra-arterial
insulin infusion and did not change from day 1 and 2 in
either of the three treatment groups.
Ambulatory 24 hour blood pressure and pulse
measurement
Data on systolic and diastolic blood pressure and heart
rate on the two examination days during ambulatory
24-hour blood pressure measurement and heart rate
measurement are presented in Figure 6. Both systolic,
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Figure 4 Baseline forearm glucose uptake.F o r e a r mg l u c o s e
uptake during insulin infusion. Patients with heart failure compared
to healthy controls.
Time (minutes)
03 0 6 0
G
l
u
c
o
s
e
 
u
p
t
a
k
e
 
[
m
m
o
l
/
m
i
n
]
0
1
2
3
4
5
At baseline with Carvedilol
After randomization to Carvedilol
p=0.94
Time [minutes]
03 0 6 0
G
l
u
c
o
s
e
 
u
p
t
a
k
e
 
[
m
m
o
l
/
m
i
n
]
0
1
2
3
4
5
Before Metoprolol Succinate
After Metoprolol Succinate
p=0.58
Time [minutes]
03 0 6 0
G
l
u
c
o
s
e
 
u
p
t
a
k
e
 
[
m
m
o
l
/
m
i
n
]
0
1
2
3
4
5
Before Metoprolol Tartrate
After Metoprolol Tartrate
p=0.92
Figure 5 Forearm glucose uptake. Forearm glucose uptake during
insulin infusion, before and after the treatment period with
carvedilol, metoprolol succinate and metoprolol tartrate respectively.
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Page 7 of 10diastolic blood pressure as well as heart rate measure-
ments were comparable in the three treatment groups at
t h eb e g i n n i n go ft h es t u d ya n dd i dn o tc h a n g et w o
months after switching beta blocker treatment from car-
vedilol to metoprolol succinate or metoprolol tartrate.
Discussion
In this study we examined vascular and hemodynamic
effects of changing beta blocker treatment from carvedi-
lol to metoprolol succinate or metoprolol tartrate in
patients with documented heart failure. In our study,
endothelial function was not changed from switching
beta blocker treatment from carvedilol to either meto-
prolol succinate or metoprolol tartrate. Previous studies
have indicated that treatment with carvedilol could
improve endothelial function in patients with coronary
artery disease [13] and in patients with dilated cardio-
myopathy [14]. Studies have shown that endothelial
function is associated with NYHA class [15]. In our
study all patients were stable with mild heart failure
NYHA I-II, also after changing treatment with beta
blockers. This fact that patients had mild HF, could
have influenced the fact that we were not able to
demonstrate a change in endothelial function after
switching the beta blocker treatment from carvedilol to
metoprolol, neither the succinate or tartrate formulation
(Figure 2). Most patients in this study were treated with
both statins as well as ACE inhibitors or AT II antago-
nists known to improve endothelial function in patients
with heart failure [16,17]. The fact that we were not
able to demonstrate an impaired endothelial function in
patients with HF, could be explained by the concomitant
medication, known to improve endothelial function. The
concomitant medication could impact endothelial func-
tion throughout the study period and influence the fact
that we were not able to demonstrate a difference in
endothelial function after changing beta blocker treat-
ment from carvedilol to metoprolol. Also the fact that
co-existence of diabetes is associated with blunted
endothelial function [15] might have influenced the
results of our study. In the group of patients rando-
mized to a treatment with either carvedilol or metopro-
lol succinate there were three patients with co-existing
diabetes in each group, whereas there were no patients
with diabetes in the group randomized to a treatment
with metoprolol tartrate. Even though, we found no
change after multivariable analysis including co-exis-
tence of diabetes.
HF can be regarded as an insulin resistant state with
increased risk of diabetes [18]. We have found that the
studied group of patients with HF were vascular insulin
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Figure 6 Blood pressure and pulse. Differences in systolic blood
pressure, diastolic blood pressure and heart rate before and after
the two month treatment period with carvedilol, metoprolol
succinate and metoprolol tartrate respectively.
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Page 8 of 10resistant and had a reduced forearm glucose uptake
when compared to healthy controls Beta blockers, as a
group, were initially thought to worsen metabolic glu-
cose control, but there have been shown important dif-
ferences between individual beta blockers. In The
Glycemic Effects in Diabetes Mellitus: Carvedilol-Meto-
prolol Comparison in Hypertensives study (GEMINI),
patients with diabetes mellitus (DM) and hypertension
treated with metoprolol tartrate had a deteriorated
metabolic control when compared to patients treated
with carvedilol [7]. In the COMET study more cases of
new-onset diabetes occurred in the metoprolol group
compared to the carvedilol group [8]. In this study we
found no difference in either insulin-stimulated vasodi-
latation or forearm glucose uptake when changing
patients from carvedilol to neither metoprolol tartrate
nor metoprolol succinate treatment (Figure 3). From the
result of our study we could not find a vascular reaction
as the explanation for the changes observed in the
COMET study between treatment with metoprolol and
carvedilol. In a previous study we found that patients
with type 2 diabetes had impaired insulin stimulated
vasodilatation when treated with metoprolol compared
to those treated with carvedilol [9]. The HF patients
were already treated with carvedilol as we found that
they were vascular insulin resistant, but changing this
treatment did not change the result. We did not see any
systemic changes in metabolic control either.
Different groups of beta blockers might have different
effects on blood pressure and heart rate. We therefore did
a 24-hour ambulatory blood pressure and heart rate mea-
surement in a subgroup of patients from all three treat-
ment groups. When testing the patients on first carvedilol
treatment, since treatment with either metoprolol tartrate
or metoprolol succinate, we found no difference between
the beta blocker treatment groups. In a study by Sander-
son a 24-hour heart rate evaluation was done in patients
with HF; they compared treatment with carvedilol and
metoprolol tartrate and found no difference in diurnal
heart rate [10]. In our study we examined groups treated
with either metoprolol tartrate or metoprolol succinate at
comparable doses and found no changes in either diurnal
blood pressure or heart rate. This indicates that metopro-
lol tartrate instead of metoprolol succinate did not cause a
different effect of beta1-adrenergic blockade at doses cho-
sen in our study. In a direct comparison among patients
with HF, no differences in hemodynamic parameters were
found either between treatments with metoprolol tartrate
or metoprolol succinate at equal doses [19].
Study Limitation
Our patients were already treated with carvedilol at the
first examination of endothelial function. Methodologi-
cally, it would have been an advantage to the study if
patients were beta blocker naïve at entering the study.
We found it unethical to withdraw beta blocker treat-
ment in patients with a proven benefit of treatment
and risk of worsening of heart failure symptoms in the
situation of withdrawal of beta blocker treatment.
A limitation to the study could be the relative small
number of patients included. With 9 patients in each
g r o u pw ew e r en o ta b l et os h o wa n yd i f f e r e n c ei n
endothelial function between different beta blocker
treatments. The fact that we did not find any difference
in endothelial function could be explained by the short
treatment period and a risk of a carry over effect.
Conclusion
In our study we found no changes in vascular reactivity
in patients with mild HF by changing treatment from
carvedilol to metoprolol tartrate or metoprolol succi-
nate. Previous studies with metabolic advantages of car-
vedilol compared to metoprolol were not reflected in
our study of forearm glucose uptake; no changes were
seen between carvedilol or metoprolol treatment. Diur-
nal blood pressure and heart rate measurement indicate
that treatment with carvedilol and metoprolol, both suc-
cinate and tartrate formulation is comparable regarding
the beta1-adrenergic blocking effect.
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